Ling Xue

Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib

Jennifer A. Woyach, Richard R. Furman, Ta-Ming Liu et al. · New England Journal of Medicine · 2014 · 1.3K citations · Full text

Medicine, Oncology, Pharmacology +14

Paclitaxel (Taxol): An Inhibitor of Angiogenesis in a Highly Vascularized Transgenic Breast Cancer

Derick Lau, Ling Xue, Lawrence J.T. Young et al. · Cancer Biotherapy and Radiopharmaceuticals · 1999 · 171 citations

Medicine, Oncology, Pharmacology +16

Fas-associated death domain (FADD) is a negative regulator of T-cell receptor–mediated necroptosis

Stephanie L. Osborn, Gretchen E. Diehl, Seong‐Ji Han et al. · Proceedings of the National Academy of Sciences · 2010 · 153 citations · Full text

Life Sciences, Cell Biology, Immunology +17

3,3′-Diindolylmethane Is a Novel Mitochondrial H+-ATP Synthase Inhibitor that Can Induce p21Cip1/Waf1 Expression by Induction of Oxidative Stress in Human Breast Cancer Cells

Yixuan Gong, Hee‐Sook Sohn, Ling Xue et al. · Cancer Research · 2006 · 148 citations

Life Sciences, Oncology, Pharmacology +17

Histone Methyltransferase NSD2/MMSET Mediates Constitutive NF-κB Signaling for Cancer Cell Proliferation, Survival, and Tumor Growth via a Feed-Forward Loop

Ping Yang, Linlang Guo, Zhijian Duan et al. · Molecular and Cellular Biology · 2012 · 143 citations · Full text

Life Sciences, Molecular Biology, Oncology +17